Rosen Law Firm reminds purchasers of Regado Biosciences securities
(NASDAQ:RGDO) including open market purchasers and those who purchased
in Regado's IPO between August 22, 2013 and July 9, 2014 of the
important September 8, 2014 lead plaintiff deadline in the class action.
To join the Regado class action, go to the website at http://rosenlegal.com/cases-305.html
or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653
or email firstname.lastname@example.org or email@example.com
for information on the class action.
According to the lawsuit, defendants made inaccurate statements of
material fact or failed to disclose in its IPO documents: (1) the
administration of Revolixys presented a significant risk of severe
allergic reaction, which substantially undermined Revolixys' potential
to become the new standard of care for anticoagulation therapy for
patients undergoing cardiovascular procedures such as percutaneous
coronary intervention ("PCI") to open or widen obstructed coronary
arteries; and (2) the Company's positive statements about Revolixys'
clinical development and potential to become the standard of care for
anticoagulation therapy for patients undergoing PCI and other
cardiovascular procedures, were materially false and misleading or
lacked a reasonable basis. The lawsuit claims that when this adverse
information entered the market, the price of Regado shares dropped,
A class action lawsuit has already been filed. If you wish to serve as
lead plaintiff, you must move the Court no later than September 8, 2014.
If you wish to join the litigation or to discuss your rights or
interests regarding this class action, please contact, Phillip Kim, Esq.
or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or
via e-mail at firstname.lastname@example.org
The Rosen Law Firm focuses on prosecuting securities class action
litigation and actions involving financial fraud. The Rosen Law Firm
represents investors throughout the globe.
[ Back To NFVZone's Homepage ]